Last reviewed · How we verify
DI-Leu16-IL2 immunocytokine
DI-Leu16-IL2 immunocytokine is a Biologic drug developed by City of Hope Medical Center. It is currently in Phase 1 development. Also known as: de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2, DI-Leu16-IL-2.
At a glance
| Generic name | DI-Leu16-IL2 immunocytokine |
|---|---|
| Also known as | de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2, DI-Leu16-IL-2 |
| Sponsor | City of Hope Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL (PHASE1, PHASE2)
- A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL (PHASE1, PHASE2)
- Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DI-Leu16-IL2 immunocytokine CI brief — competitive landscape report
- DI-Leu16-IL2 immunocytokine updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI
Frequently asked questions about DI-Leu16-IL2 immunocytokine
What is DI-Leu16-IL2 immunocytokine?
DI-Leu16-IL2 immunocytokine is a Biologic drug developed by City of Hope Medical Center.
Who makes DI-Leu16-IL2 immunocytokine?
DI-Leu16-IL2 immunocytokine is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).
Is DI-Leu16-IL2 immunocytokine also known as anything else?
DI-Leu16-IL2 immunocytokine is also known as de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2, DI-Leu16-IL-2.
What development phase is DI-Leu16-IL2 immunocytokine in?
DI-Leu16-IL2 immunocytokine is in Phase 1.
Related
- Manufacturer: City of Hope Medical Center — full pipeline
- Also known as: de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2, DI-Leu16-IL-2
- Compare: DI-Leu16-IL2 immunocytokine vs similar drugs
- Pricing: DI-Leu16-IL2 immunocytokine cost, discount & access